Zipalertinib - Cullinan Therapeutics
Alternative Names: CLN-081; TAS-6417; TPC-064Latest Information Update: 03 Feb 2025
At a glance
- Originator Taiho Pharmaceutical
- Developer Cullinan Therapeutics; Taiho Pharmaceutical
- Class Acrylamides; Amines; Antineoplastics; Indolizines; Pyrimidines; Quinolines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
Most Recent Events
- 03 Feb 2025 Updated efficacy data from the phase I/II REZILIENT1 trial in Non-small cell lung cancer released by Cullinan Therapeutics
- 28 Jan 2025 Taiho Pharmaceutical and Cullinan Therapeutics plan to submit NDA to US FDA for Non small cell lung cancer in the second half of 2025
- 14 Sep 2024 Efficacy and adverse events data from a phase I/II REZILIENT1 trial in Non-small cell lung cancer released by Cullinan Therapeutics